The statins as anticancer agents.
暂无分享,去创建一个
[1] D. Illingworth. Carcinogenicity of lipid-lowering drugs. , 1996, JAMA.
[2] H. Yeger,et al. Lovastatin-induced Apoptosis of Human Medulloblastoma Cell Lines in vitro , 1999, Journal of Neuro-Oncology.
[3] D. Samid,et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] S. Yusuf,et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.
[5] S. Broitman,et al. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. , 1996, Advances in experimental medicine and biology.
[6] R. Laaksonen,et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. , 1996, The American journal of cardiology.
[7] T. Gross,et al. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. , 1990, JAMA.
[8] C. Hennekens,et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.
[9] T. Mutoh,et al. Role of tyrosine phosphorylation of phospholipase C γ1 in the signaling pathway of HMG‐CoA reductase inhibitor‐induced cell death of L6 myoblasts , 1999, FEBS letters.
[10] R. Laaksonen,et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short‐term simvastatin treatment in humans , 1995, Clinical pharmacology and therapeutics.
[11] R. Law,et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. , 1994, Biochemical and biophysical research communications.
[12] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[13] M. Onoda,et al. Anti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. , 1997, Carcinogenesis.
[14] M. Kuroda,et al. Citrinin, an inhibitor of cholesterol synthesis. , 1976, The Journal of antibiotics.
[15] H. Nakagawa,et al. HMG‐CoA reductase inhibitor‐induced L6 myoblast cell death: involvement of the phosphatidylinositol 3‐kinase pathway , 1998, FEBS letters.
[16] E. Laws,et al. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. , 1998, American journal of clinical oncology.
[17] A. Gotto,et al. Pleiotropic effects of statins: do they matter? , 2001, Current opinion in lipidology.
[18] T. Stokłosa,et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] R. Gherardi,et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. , 1993, The American journal of medicine.
[20] H. Pan,et al. Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin , 1990, Journal of clinical pharmacology.
[21] C. Furberg,et al. Reductase inhibitor monotherapy and stroke prevention. , 1997, Archives of internal medicine.
[22] F. Frerman,et al. LOVASTATIN, ISOPRENES, AND MYOPATHY , 1989, The Lancet.
[23] D. Kornbrust,et al. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. , 1989, The Journal of pharmacology and experimental therapeutics.
[24] M. Kitagawa,et al. Geranylgeranylated Rho Small GTPase(s) Are Essential for the Degradation of p27Kip1 and Facilitate the Progression from G1 to S Phase in Growth-stimulated Rat FRTL-5 Cells* , 1997, The Journal of Biological Chemistry.
[25] M. Alberts,et al. Suppression of recurrent transient ischemic attacks by a statin agent , 2001, Neurology.
[26] A. De Luca,et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. , 1995, The Journal of pharmacology and experimental therapeutics.
[27] T. Mjörndal,et al. HMG-CoA Reductase Inhibitors and Myotoxicity , 2000, Drug safety.
[28] T. Narisawa,et al. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. , 1996, The Tohoku journal of experimental medicine.
[29] D. Catovsky,et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice , 1998, British journal of haematology.
[30] F Gutzwiller,et al. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. , 2000, The American journal of clinical nutrition.
[31] O. Scharovsky,et al. Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. , 1998, Cancer biotherapy & radiopharmaceuticals.
[32] T. Narisawa,et al. Chemoprevention by Pravastatin, a 3‐Hydroxy‐3‐methylglutaryl‐coenzyme A Reductase Inhibitor, of N‐Methyl‐N‐nitrosourea‐induced Colon Carcinogenesis in F344 Rats , 1996, Japanese journal of cancer research : Gann.
[33] S. Grossman,et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. , 1991, The Journal of pharmacology and experimental therapeutics.
[34] Michael F. Oliver,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.
[35] Y. Nagata,et al. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells , 1997, Journal of Neuro-Oncology.
[36] H. Yeger,et al. HMG–CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P–glycoprotein–expressing cells , 1996, Nature Medicine.
[37] M. Tatsuta,et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. , 2001, Cancer research.
[38] M. Lishner,et al. Effect of Simvastatin Alone and in Combination With Cytosine Arabinoside on the Proliferation of Myeloid Leukemia Cell Lines , 2001, Journal of Investigative Medicine.
[39] D. Samid,et al. Increased radioresistance of ejras‐transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation , 1993, International journal of cancer.
[40] S. Kritchevsky. Dietary lipids and the low blood cholesterol-cancer association. , 1992, American journal of epidemiology.
[41] G. Guyatt,et al. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. , 1998, Annals of internal medicine.
[42] R. Danesi,et al. Geranylgeraniol Overcomes the Block of Cell Proliferation by Lovastatin in C6 Glioma Cells , 1998, Journal of neurochemistry.
[43] B. Davis,et al. Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.
[44] J. Stein,et al. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. , 2001, Carcinogenesis.
[45] J. Gołąb,et al. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. , 1998, European journal of cancer.
[46] P. Edwards,et al. Signaling molecules derived from the cholesterol biosynthetic pathway. , 1997, Sub-cellular biochemistry.
[47] M. Minden,et al. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells , 2001, Leukemia.
[48] M. Tarnopolsky,et al. Statin myopathies: pathophysiologic and clinical perspectives. , 2001, Clinical and investigative medicine. Medecine clinique et experimentale.
[49] R. Gregg,et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. , 1995, Toxicology and applied pharmacology.
[50] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[51] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[52] M. Marcelli,et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. , 1998, Cancer research.
[53] S. Specht,et al. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. , 1993, Invasion & metastasis.
[54] M. Minden,et al. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] B. Halmos,et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] C. Ling,et al. The role of the H-ras oncogene in radiation resistance and metastasis. , 1990, International journal of radiation oncology, biology, physics.
[57] J. Larosa,et al. Pleiotropic effects of statins and their clinical significance. , 2001, The American journal of cardiology.
[58] J. Farmer. Pleiotropic effects of statins , 2000, Current atherosclerosis reports.
[59] S. Pazzaglia,et al. Sensitivity of C3H 10T1/2 cells to radiation-induced killing and neoplastic transformation as a function of cell cycle. , 1996, International journal of radiation biology.
[60] D. Samid,et al. Lipid Metabolism as a Target for Brain Cancer Therapy: Synergistic Activity of Lovastatin and Sodium Phenylacetate Against Human Glioma Cells , 1996, Journal of neurochemistry.
[61] A. De Luca,et al. Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. , 1999, European journal of pharmacology.
[62] A. Oza,et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. , 2005, European journal of cancer.
[63] P. Edwards,et al. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. , 1999, Annual review of biochemistry.
[64] G. Stoner,et al. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. , 1996, Cancer letters.
[65] B. Foster,et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line , 1999, Oncogene.
[66] R. Stocker,et al. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[67] Xiao-Fan Wang,et al. Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21 WAF1/CIP1 in Human Prostate Carcinoma Cells* , 1998, The Journal of Biological Chemistry.
[68] M. Law,et al. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies , 1991, Cancer Causes & Control.
[69] D. Vordermark,et al. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. , 2000, Anticancer research.
[70] J. D. Karkas,et al. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. , 1989, Biochemical and biophysical research communications.
[71] J. Soria,et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. , 2001, Carcinogenesis.
[72] Y. Shibamoto,et al. High-dose intraoperative radiotherapy for unresectable pancreatic cancer. , 1996, International journal of radiation oncology, biology, physics.
[73] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[74] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[75] D. Gomez,et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis , 1998, Breast Cancer Research and Treatment.
[76] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[77] Y. Konishi,et al. Delay in administration of CDDP until completion of AGM-1470 treatment enhances antimetastatic and antitumor effects , 1999, Clinical & Experimental Metastasis.
[78] G. Ness,et al. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. , 1996, Archives of biochemistry and biophysics.
[79] G. Butti,et al. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. , 1992, Cancer research.
[80] Keunchil Park,et al. Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma , 2004, Investigational New Drugs.
[81] R. Kratzke,et al. Lovastatin induces apoptosis in malignant mesothelioma cells. , 1998, American journal of respiratory and critical care medicine.
[82] R. Bonfil,et al. Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma , 1999, Clinical & Experimental Metastasis.
[83] J. LeLorier,et al. Do statins cause cancer? A meta-analysis of large randomized clinical trials. , 2001, The American journal of medicine.
[84] D. Lowy,et al. Inhibition of cell growth by lovastatin is independent of ras function. , 1991, Cancer research.
[85] L. Blais,et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.
[86] F. Bernini,et al. Non-lipid-related effects of statins , 2000, Annals of medicine.
[87] M. Linton,et al. Current perspectives on statins. , 2000, Circulation.
[88] M. Moghadasian. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. , 1999, Life sciences.
[89] C. Coleman,et al. Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells. , 1995, Radiation research.
[90] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[91] M. Law,et al. Assessing possible hazards of reducing serum cholesterol , 1994, BMJ.
[92] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[93] H. Bundgaard,et al. HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density. , 2000, Cardiovascular research.
[94] J. Tobert. Efficacy and long-term adverse effect pattern of lovastatin. , 1988, The American journal of cardiology.
[95] G. Thorgeirsson,et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. , 2000, The American journal of cardiology.
[96] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[97] R. Hohl,et al. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. , 2001, Leukemia research.
[98] K. Keyomarsi,et al. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. , 1991, Cancer research.
[99] J. Farmer,et al. Comparative Tolerability of the HMG-CoA Reductase Inhibitors , 2000, Drug safety.
[100] J. Goldstein,et al. Regulation of the mevalonate pathway , 1990, Nature.
[101] Y. Matsuzawa,et al. Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial , 2022 .
[102] A. Dabrowska,et al. Lovastatin and tumor necrosis factor‐α exhibit potentiated antitumor effects against Ha‐ras‐transformed murine tumor Via inhibition of tumor‐induced angiogenesis , 1999, International journal of cancer.
[103] L. Penn,et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.